Given the precondition of the participant role.

Fluconazole (Diflucan; Pfizer, Inc., New York, NY) is a synthetic triazole antifungal functionary with human action against a wide difference of pathogenic leaven, including Candida albicans and Candida tropicalis. Potentially resistant strains include Candida glabrata, Candida lusitaniae, and Candida krusei. Fluconazole has gained wide clinical bill of exchange because of its favorable pharmacokinetics and excellent guard cross section. In healthy subjects and patients not in an intensive care unit (ICU), fluconazole is almost completely absorbed, with an absolute bioavailability of 90% after oral direction, and exhibits a half-life of approximately 30 minute, which allows for once-daily dosing. Fluconazole is eliminated predominantly by the kidneys; renal interval accounts for 80% of amount license.
In critically ill patients, fluconazole pharmacokinetic parameters, like those of other drugs, are likely to be very different from those in healthy subjects. This divergence is due, in part, to the effects on permission and state of mind by compromised reed organ duty (renal, hepatic, and gastrointestinal) and the effects on sound property of dispersion by matter shifts and tubing permeability changes. Given the precondition of the participant role, the need to understand these pharmacokinetic differences and the opening need for dose adjustments may be even more critical.